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To the Editor:
“Addressing  the  Obesity  Epidemic:  A  Genomics 
Perspective”  in  your  April  2007  (1)  issue  speaks  of 
the  importance  of considering  all  aspects  of  obesity. 
However, one  aspect overlooked  in  the  article is  weight 
gain  associated  with medical  treatment. Many  classes 
of  drugs  are  associated  with  weight  gain  that  leads  to 
overweight  or  obesity;  these  include  atypical  antipsy-
chotic drugs, lithium, some antidepressant drugs, some 
antiepileptic drugs, and some steroids. Other drugs are 
associated  with fat  redistribution  (e.g.,  some  drugs  for 
HIV/AIDS).
In addition to increasing weight, atypical antipsychotic 
drugs increase risk for hyperglycemia (as noted in a black-
box label required by the Food and Drug Administration 
[FDA]),  and  they  are  associated  with lipid  dysregula-
tion  (2).  Atypical  antipsychotic  drugs  induce  excitation 
and hypomania or mania, adverse effects never reported 
for  the  older  versions  of  typical  antipsychotic  drugs 
(3). Some atypical antipsychotic drugs are also noncardiac 
QTc-interval–prolonging  drugs  and  are  associated  with 
increased sudden cardiac death (4).   
Atypical  antipsychotic  drugs  are  widely  used  off-
label. The  FDA  issued  a  Public  Health  Advisory  warn-
ing of a 60% to 70% increased risk for mortality among 
elderly people with dementia being treated with atypical 
antipsychotic medications (5). From 1993 through 2002, 
prescriptions for atypical antipsychotic drugs for Ameri-
can children increased 500% (all off-label); 85% of those 
prescriptions  were  for  nonpsychotic  conditions  (6). The 
public health implications of wide off-label use of this class 
of drugs merits more study.
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